Your browser doesn't support javascript.
loading
Ad26.COV2.S breakthrough infections induce high titers of antibodies capable of neutralizing variants of concern
Dale Kitchin; Simone I Richardson; Mieke A van der Mescht; Thopisang Motlou; Nonkululeko Mzindle; Thandeka Moyo-Gwete; Zanele Makhado; Frances Ayres; Nelia P Manamela; Holly Spencer; Bronwen Lambson; Brent Oosthuysen; Haajira Kaldine; Marizane du Pisanie; Mathilda Mennen; Sango Skelem; Noleen Williams; Ntobeko A B Ntusi; Wendy A Burgers; Glenda G Gray; Linda-Gail Bekker; Michael T Boswell; Theresa M Rossouw; Veronica Ueckermann; Penelope Linda Moore.
Afiliación
  • Dale Kitchin; National Institute for Communicable Diseases
  • Simone I Richardson; National Institute for Communicable Diseases
  • Mieke A van der Mescht; University of Pretoria
  • Thopisang Motlou; National Institute for Communicable Diseases
  • Nonkululeko Mzindle; National Institute for Communicable Diseases
  • Thandeka Moyo-Gwete; National Institute for Communicable Diseases
  • Zanele Makhado; National Institute for Communicable Diseases
  • Frances Ayres; National Institute for Communicable Diseases
  • Nelia P Manamela; National Institute for Communicable Diseases
  • Holly Spencer; National Institute for Communicable Diseases
  • Bronwen Lambson; National Institute for Communicable Diseases
  • Brent Oosthuysen; National Institute for Communicable Diseases
  • Haajira Kaldine; National Institute for Communicable Diseases
  • Marizane du Pisanie; University of Pretoria
  • Mathilda Mennen; University of Cape Town
  • Sango Skelem; University of Cape Town
  • Noleen Williams; University of Cape Town
  • Ntobeko A B Ntusi; University of Cape Town
  • Wendy A Burgers; University of Cape Town
  • Glenda G Gray; South African Medical Research Council
  • Linda-Gail Bekker; University of Cape Town
  • Michael T Boswell; University of Pretoria
  • Theresa M Rossouw; University of Pretoria
  • Veronica Ueckermann; University of Pretoria
  • Penelope Linda Moore; National Institute for Communicable Diseases
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21266049
ABSTRACT
The Janssen (Johnson & Johnson) Ad26.COV2.S non-replicating viral vector vaccine has been widely deployed for COVID-19 vaccination programs in resource-limited settings. Here we confirm that neutralizing and binding responses to Ad26.COV2.S vaccination are stable for 6 months post-vaccination, when tested against multiple SARS-CoV-2 variants. Secondly, using longitudinal samples from individuals who experienced clinically mild breakthrough infections 4 to 5 months after vaccination, we show dramatically boosted binding antibodies, Fc effector function and neutralization. These high titer responses are of similar magnitude to humoral immune responses measured in severely ill, hospitalized donors, and are cross-reactive against diverse SARS-CoV-2 variants, including the extremely neutralization resistant Omicron (B.1.1.529) variant that currently dominates global infections, as well as SARS-CoV-1. These data have implications for population immunity in areas where the Ad26.COV2.S vaccine has been widely deployed, but where ongoing infections continue to occur at high levels.
Licencia
cc_by
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Prognostic_studies / Rct Idioma: En Año: 2021 Tipo del documento: Preprint
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Prognostic_studies / Rct Idioma: En Año: 2021 Tipo del documento: Preprint